ello, everyone, and welcome to another working week. It’s nice to see you again after our extended respite, which was exciting and fast-paced. Now, though, the usual routine has returned. But we all knew this would happen, yes? So as a shiny sun warms the Pharmalot campus this morning, we are brewing cups of stimulation, playing catch-up and assembling tidbits for your pleasure. Hope you have a smashing day and do stay in touch …
Hillary Clinton has taken more money in donations from employees of the 15 biggest US drug makers than all of the Republicans who attempted to run for president this year combined, according to Reuters, citing campaign finance disclosures. Clinton’s campaign took nearly $240,000 through the end of April, compared with nearly $168,000 for all of the Republicans together, including around $1,700 for Donald Trump, according to the filings.
The UK’s National Institute for Health and Care Excellence reiterated an earlier decision that Vertex Pharmaceuticals’s Orkambi cystic fibrosis treatment does not justify its “considerable cost,” PharmaTimes says. “We can only recommend treatments when we are certain they are both clinically effective and represent good value for money,” said professor Carole Longson, director of the NICE Center for Health Technology Evaluation.
GlaxoSmithKline is having manufacturing problems at a factory in Italy, disrupting production of some drugs and leading to shortages of the widely used Ultiva opioid anesthetic in Denmark, Reuters tells us. Late last week, the company temporarily suspended manufacturing at its Parma site, which makes sterile products, to investigate environmental monitoring, but maintained this was unrelated to risks from any medicines.
Mexican authorities didn’t know that the owner of the nation’s leading pharmaceutical distributor was actually behind the purchase of a rival when they approved the deal last year, the Wall Street Journal reports.
The directors behind “Making A Murderer” are planning an adaptation of an investigation into the Johnson & Johnson scandal surrounding the marketing of the Risperdal antipsychotic, Huffington Post tells us.
The UK’s National Institute for Health and Care Excellence endorsed the use of Bristol-Myers Squibb’s immunotherapy combination Opdivo/Yervoy to treat patients with advanced melanoma, PMLive writes.
A trial of Merck’s Keytruda drug found that advanced lung cancer patients who were previously untreated went longer without worsening and showed a survival advantage over those given chemotherapy, Reuters says.
An Eli Lilly executive told analysts that its drugs are more prone to price pressure than newer ones, according to Bloomberg News.
A plan to charge drug makers located in India more to import ingredients won support of the government’s Drugs Technical Advisory Board, Outsourcing Pharma says.
Novartis’s Sandoz generics unit plans to sell eight biosimilars, compared with three now, by 2020 as patents on original drugs expire, PharmaTimes writes.
The Supreme People’s Court of China rejected an appeal by Eli Lilly, which maintained that Changzhou Watson Pharmaceutical infringed the patent of its Zyprexa antipsychotic, China Daily reports
Johnson & Johnson filed a second patent lawsuit against Celltrion and Pfizer to stop them from launching a biosimilar version of its Remicade arthritis and inflammatory bowel drug in the US, Reuters says.